NVP-TAE684-resistant ALK mutants

Stable Identifier
R-HSA-9717301
Type
Pathway
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this pathway in the Pathway Browser

NVP TAE684 is a second generation tyrosine kinase inhibitor with activity against some ALK mutants, including some that show resistance to crizotinib (George et al, 2008; Sasaki et al, 2011; Heuckmann et al, 2011; Ceccon et al, 2013). This pathway describes ALK mutants that show resistance to inhibition by NVP TAE684.

Literature References
PubMed ID Title Journal Year
21948233 ALK mutations conferring differential resistance to structurally diverse ALK inhibitors

Lovly, CM, Grütter, C, Heynck, S, Sos, ML, Thomas, RK, Peifer, M, Balke-Want, H, Heuckmann, JM, Rauh, D, Koker, M, Weiss, J, Pao, W, Hölzel, M

Clin. Cancer Res. 2011
18923525 Activating mutations in ALK provide a therapeutic target in neuroblastoma

Zozulya, S, George, RE, Gilliland, DG, Morris, SW, Luther, W, London, WB, Hanna, M, Meyerson, M, McGrady, P, Sanda, T, Gregor, VE, Look, AT, Zhang, J, Fröhling, S, Ahn, Y, Diller, L, Webb, TR, Zhou, W, Greulich, H, Gray, NS, Xue, L

Nature 2008
23239810 Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors

Ceccon, M, Mologni, L, Scapozza, L, Bisson, W, Gambacorti-Passerini, C

Mol. Cancer Res. 2013
21791641 A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors

Zheng, W, Lindeman, N, Capelletti, M, Gray, NS, Wong, KK, Christensen, JG, Ercan, D, Jänne, PA, Rodig, SJ, Shimamura, T, Nikiforow, S, Weremowicz, S, Sasaki, T, Okuda, K, Wilner, K, Eck, MJ, Butaney, M, Stumpfova, M, Yanagita, M, Heon, S, Ogino, A, Xiao, Y, Marcoux, JP, Koivunen, J, Lathan, C, Du, J

Cancer Res. 2011
Participants
Participates
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Authored
Reviewed
Created
Cite Us!